The development of five new monoclonal antibodies against human DUX4 provides a tool for investigating FSHD pathogenesis and demonstrates differential toxicity of DUX4 isoforms in human muscle cells.
Authors
No takes yet. Share an insight, caveat, or question.
Differential DUX4 isoform toxicity in muscle cells warrants isoform-selective caution; leaves open targeted FSHD therapies and antibody tools for validation.
Geng et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: